CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

The DNA hypomethylating drug decitabine maintains normal hematopoietic stem cell (HSC) self-renewal but induces terminal differentiation in acute myeloid leukemia (AML) cells. The basis for these contrasting cell-fates, and for selective CpG hypomethylation by decitabine, is poorly understood. Promo...

Descripción completa

Detalles Bibliográficos
Autores principales: Negrotto, Soledad, Ng, Kwok Peng, Jankowska, Ania M., Bodo, Juraj, Gopalan, Banu, Guinta, Kathryn, Mulloy, James C., Hsi, Eric, Maciejewski, Jaroslaw, Saunthararajah, Yogen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217177/
https://www.ncbi.nlm.nih.gov/pubmed/21836612
http://dx.doi.org/10.1038/leu.2011.207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217177/
https://www.ncbi.nlm.nih.gov/pubmed/21836612
http://dx.doi.org/10.1038/leu.2011.207

Ejemplares similares